dc.contributor.author | World Health Organization | |
dc.coverage.spatial | Geneva | en_US |
dc.date.accessioned | 2017-05-18T13:41:42Z | |
dc.date.available | 2017-05-18T13:41:42Z | |
dc.date.issued | 2017-04 | |
dc.identifier.uri | https://iris.who.int/handle/10665/255487 | |
dc.description | 26 p. | en_US |
dc.language.iso | en | en_US |
dc.publisher | World Health Organization | en_US |
dc.rights | CC BY-NC-SA 3.0 IGO | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/3.0/igo | en_US |
dc.subject.mesh | Drugs, Essential | en_US |
dc.subject.mesh | Safety Management | en_US |
dc.subject.mesh | Drug Monitoring | en_US |
dc.subject.mesh | Periodical | en_US |
dc.subject.mesh | Pharmacovigilance | |
dc.title | WHO pharmaceuticals newsletter: 2017, No. 2 | en_US |
dc.type | Journal / periodical articles | en_US |
dc.rights.holder | World Health Organization | en_US |
dc.description.startpage | 1 | en_US |
dc.description.endpage | 26 | en_US |
dc.relation.ispartofjournal | WHO pharmaceuticals newsletter | en_US |
dc.relation.issue | 2 | en_US |